AMINOPEPTIDASE N RESPONSIVE RESORUFIN-BASED PHOTOTHERANOSTIC AGENT FOR SELECTIVE TREATMENT OF CANCER CELLS

2023-9-5
Sayın, Büşra Asena
Advancements in cancer therapy continue to evolve, with targeted approaches offering the potential for improved treatment outcomes and reduced side effects. This study explores the utilization of the aminopeptidase N (APN)-responsive resorufin-based photodynamic therapy (PDT) agent, RA-1 for targeted cancer therapy. The investigation includes both the photophysical characterization of RA-1 and its in vitro applications. Photophysical characterization involved analysis of RA-1's reactivity through fluorescence and absorbance measurements. These experiments highlighted the specific activation of RA-1 in response to APN enzymatic activity and time dependent release of the core molecule upon APN exposure. Selectivity of RA-1's activation mechanism was examined through selectivity experiments. These studies established the exquisite selectivity of RA-1's response to APN, further validating its potential as a targeted therapy agent. In vitro photodynamic therapy efficacy of RA-1 was also evaluated. Dark toxicity assessments confirmed the non-toxic nature of RA-1 in the absence of light. PDT treatment experiments demonstrated that RA-1 induced cytotoxicity specifically in APN overexpressing HT1080 cancer cells while maintaining the viability of healthy L929 cells. In order to provide additional evidence about the specificity of RA-1 towards APN in vitro, PDT experiments were performed on the U-87 MG glioblastoma cell line. Despite the well-known cytotoxicity of the iodo-resorufin core in U-87 MG cells, the application of RA-1-based PDT did not exhibit significant cytotoxicity on U-87 MG cell line characterized by low APN expression level. These findings demonstrated the significant selectivity of RA-1 towards APN and indicated the potential of RA-1 on APN-overexpressing cancer cell lines.
Citation Formats
B. A. Sayın, “AMINOPEPTIDASE N RESPONSIVE RESORUFIN-BASED PHOTOTHERANOSTIC AGENT FOR SELECTIVE TREATMENT OF CANCER CELLS,” M.S. - Master of Science, Middle East Technical University, 2023.